ComGen Biopharmaceutical is a researcher and developer of innovative drugs for immunotherapy of autoimmune diseases and tumors.
Kangjing Bio focuses on the research and development of innovative drugs for the immunotherapy of autoimmune diseases and tumors. A round of financing of nearly 100 million yuan has been completed. This round of financing was jointly led by Sequoia China and Yahui Investment, followed by Fuchuang Investment and Renyou Investment. For this transaction, Hejun Capital and Chenrui Capital acted as financial advisors. This round of financing will be mainly used for phase I clinical trials of complement inhibitors under research on new targets, the advancement of other pipeline drugs, and the further consolidation of the application of innovative drug research and development platforms based on the complement system.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Nov 18, 2021 | Series A | — | 2 | Yahui Precision Medicine Fund | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Yahui Precision Medicine Fund | Yes | Series A |
Fudan Venture Capital | — | Series A |